- Home
- PEPG vs CGTX Comparison
PEPG vs CGTX Comparison
Compare PEPG & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- CGTX
- Stock Information
- Founded
- PEPG 2018
- CGTX 2007
- Country
- PEPG United States
- CGTX United States
- Employees
- PEPG N/A
- CGTX N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- PEPG Health Care
- CGTX Health Care
- Exchange
- PEPG Nasdaq
- CGTX Nasdaq
- Market Cap
- PEPG 45.9M
- CGTX 53.4M
- IPO Year
- PEPG 2022
- CGTX 2021
- Fundamental
- Price
- PEPG $1.49
- CGTX $2.41
- Analyst Decision
- PEPG Buy
- CGTX Strong Buy
- Analyst Count
- PEPG 3
- CGTX 3
- Target Price
- PEPG $7.67
- CGTX $2.83
- AVG Volume (30 Days)
- PEPG 335.1K
- CGTX 12.4M
- Earning Date
- PEPG 11-06-2025
- CGTX 08-07-2025
- Dividend Yield
- PEPG N/A
- CGTX N/A
- EPS Growth
- PEPG N/A
- CGTX N/A
- EPS
- PEPG N/A
- CGTX N/A
- Revenue
- PEPG N/A
- CGTX N/A
- Revenue This Year
- PEPG N/A
- CGTX N/A
- Revenue Next Year
- PEPG N/A
- CGTX N/A
- P/E Ratio
- PEPG N/A
- CGTX N/A
- Revenue Growth
- PEPG N/A
- CGTX N/A
- 52 Week Low
- PEPG $0.88
- CGTX $0.22
- 52 Week High
- PEPG $10.06
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- PEPG 64.86
- CGTX 61.15
- Support Level
- PEPG $1.13
- CGTX $2.26
- Resistance Level
- PEPG $1.32
- CGTX $2.67
- Average True Range (ATR)
- PEPG 0.09
- CGTX 0.40
- MACD
- PEPG 0.03
- CGTX -0.03
- Stochastic Oscillator
- PEPG 87.80
- CGTX 42.08
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.